Pyrotinib or placebo in combination with trastuzumab and docetaxel for HER2 positive metastatic breast cancer: long term survival results from randomised phase 3 PHILA trial.

BMJ · 2026 · PMC12990035 · PMID 41839514

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Nevertheless, a clear trend of benefit in overall survival rates at four and five years was still observed in the current study (73% v 64% at four years, 66% v 59% at five years).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.